Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
26 authors.
Kaname UnoDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-7762-5039
Masato YoshiharaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-5811-3137
Yoshihiko YamakitaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0009-0007-1042-9133
Kazuhisa KitamiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-9691-4728
Shohei IyoshiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-4596-2177
Mai SugiyamaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0009-0001-9843-4661
Yoshihiro KoyaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-4505-8778
Tomihiro KanayamaDepartment of Tumor Pathology, Graduate School of Medicine, Gifu University, Gifu, Japan.ORCID 0000-0001-8845-6827
Haruhito SaharaDepartment of Pathology, TOYOTA Memorial Hospital, Toyota, Japan.
Satoshi NomuraDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0009-0006-4463-754X
Kazumasa MogiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-3866-2566
Emiri MiyamotoDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroki FujimotoDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kosuke YoshidaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-1484-4872
Satoshi TamauchiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-3130-3736
Akira YokoiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-0789-5102
Nobuhisa YoshikawaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0001-8662-9421
Kaoru NiimiDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0003-4546-9606
Yukihiro ShirakiDepartment of Pathology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.ORCID 0000-0003-3666-0556
Jonas SjölundDepartment of Laboratory Medicine, Division of Translational Cancer Research, Lund University Cancer Center, Lund University, Lund, Sweden.ORCID 0000-0002-6992-3415
Hidenori OguchiDepartment of Obstetrics and Gynecology, TOYOTA Memorial Hospital, Toyota, Japan.
Kristian PietrasDepartment of Laboratory Medicine, Division of Translational Cancer Research, Lund University Cancer Center, Lund University, Lund, Sweden.ORCID 0000-0001-6738-4705
Atsushi EnomotoDepartment of Pathology, Graduate School of Medicine, Nagoya University, Nagoya, Japan.ORCID 0000-0002-9206-6116
Akihiro NawaBell Research Center, Department of Obstetrics and Gynecology Collaborative Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroyuki TomitaDepartment of Tumor Pathology, Graduate School of Medicine, Gifu University, Gifu, Japan.ORCID 0000-0002-3291-0274
Hiroaki KajiyamaDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Patients with epithelial ovarian cancer (EOC) are often diagnosed with peritoneal metastasis and ascites, the accumulation of intraperitoneal fluid containing nonmalignant cells. However, the interactions between EOC and nonmalignant cells before peritoneal metastasis remain unclear. To investigate this, whole EOC spheroids were observed using a multiphoton microscope, and their invasion ability was assessed. Mesothelial cells were identified as notable components of ascites through morphological assessment, immunohistochemical/immunofluorescence staining, and single-cell RNA sequencing analyses. Almost all EOC cells were spheroids, with 60% containing mesothelial cells. EOC cells quickly generate aggregated spheroids with mesothelial cells, and these aggregated cancer-mesothelial spheroids (ACMSs) invade collagen or mesothelial layers. Mesothelial cells forming ACMSs initiated the invasion. RNA sequencing analysis revealed marked RNA expression changes in mesothelial cells, whereas the changes in EOC cells were minor. Transforming growth factor-β1-stimulated mesothelial cells showed increased invadopodium formation along with fascin-1 up-regulation. These findings suggest that EOC cells alter mesothelial cells through ACMSs, thereby elucidating the rapid spread of EOC in the abdominal cavity.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. · full record | OpenQuestion